Related Experiment Video

Updated: May 20, 2026

Implantation of Total Artificial Heart in Congenital Heart Disease
07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

Changing face of heart failure surgery

T Yagdi1, E Oguz, C Engin

  • 1Department of Cardiovascular Surgery, Ege University Medical Faculty, Izmir, Turkey. tahir.yagdi@ege.edu.tr

Transplantation Proceedings
|July 31, 2012
PubMed

Insights

Vascular assist devices (VADs) significantly reduce mortality for heart failure patients awaiting transplants. VADs improve survival rates, allowing more patients to receive life-saving heart transplants.

Area of Science:

  • Cardiology
  • Cardiovascular Surgery
  • Medical Devices

Background:

  • Heart failure is a leading cause of death, with donor organ scarcity limiting heart transplantation success.
  • The waiting period for heart transplantation poses a significant mortality risk for end-stage heart failure patients.

Purpose of the Study:

  • To evaluate the impact of vascular assist devices (VADs) on patient outcomes in end-stage heart failure surgery.
  • To assess the role of VADs in reducing mortality among heart transplant candidates.

Main Methods:

  • Retrospective analysis of 159 heart failure patients (1998-2011), with 67 receiving VAD implantation after April 2007.
  • Comparison of outcomes for patients undergoing heart transplantation with and without prior VAD support.

Main Results:

  • VAD implantation showed no intraoperative deaths among 67 patients, with a mean support time of 214 days.
  • Overall survival to transplantation or weaning was 77.6%, with 90% survival achieved using continuous flow pumps.
  • Post-VAD introduction, nearly 80% of donor hearts were utilized for patients on mechanical circulatory support.

Conclusions:

  • Vascular assist devices have radically improved outcomes in heart failure surgery since 2007.
  • VADs significantly reduce patient loss on the waiting list for heart transplantation.
  • Mechanical circulatory support via VADs enhances the utilization of donor organs for critically ill patients.
Abstract

More Related Videos

Implantation of the Syncardia Total Artificial Heart16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...